120 related articles for article (PubMed ID: 38511642)
1. PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients.
An H; Chen S; Zhang X; Ke S; Ke J; Lu Y
Hematology; 2024 Dec; 29(1):2331389. PubMed ID: 38511642
[TBL] [Abstract][Full Text] [Related]
2. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
Li Y; Gong J; Zhang L
J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
[TBL] [Abstract][Full Text] [Related]
3. Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.
Lin W; Chen X; Zheng H; Cai Z
Hematology; 2023 Dec; 28(1):2231741. PubMed ID: 37409850
[TBL] [Abstract][Full Text] [Related]
4. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
5. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
7. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
9. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.
Ren Z; Ahn JH; Liu H; Tsai YH; Bhanu NV; Koss B; Allison DF; Ma A; Storey AJ; Wang P; Mackintosh SG; Edmondson RD; Groen RWJ; Martens AC; Garcia BA; Tackett AJ; Jin J; Cai L; Zheng D; Wang GG
Blood; 2019 Oct; 134(14):1176-1189. PubMed ID: 31383640
[TBL] [Abstract][Full Text] [Related]
10. The quantification of circular RNA 0007841 during induction therapy helps estimate the response and survival benefits to bortezomib-based regimen in multiple myeloma.
Guo Y; Feng X; Wang Z; Zhang R; Zheng K; Xu J; Hu P; Zhang R
Ir J Med Sci; 2024 Feb; 193(1):17-25. PubMed ID: 37336827
[TBL] [Abstract][Full Text] [Related]
11. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
Chim CS; Lie AK; Chan EY; Liu HS; Lau CW; Yip SF; Sim J; Wan TS; Ma ES; Liang R; Tse E; Kwong YL;
J Hematol Oncol; 2012 Jun; 5():28. PubMed ID: 22682027
[TBL] [Abstract][Full Text] [Related]
13. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
[TBL] [Abstract][Full Text] [Related]
14. PHF19 inhibition as a therapeutic target in multiple myeloma.
Schinke CD; Bird JT; Qu P; Yaccoby S; Lyzogubov VV; Shelton R; Ling W; Boyle EM; Deshpande S; Byrum SD; Washam C; Mackintosh S; Stephens O; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Barlogie B; van Rhee F; Walker BA
Curr Res Transl Med; 2021 Jul; 69(3):103290. PubMed ID: 33894670
[TBL] [Abstract][Full Text] [Related]
15. Correlation of A-Kinase Interacting Protein 1 With Clinical Features, Treatment Response, and Survival Profiles in Patients With Multiple Myeloma.
Wang W; Xie Y; Han X; Liu Y; Li P
Technol Cancer Res Treat; 2020; 19():1533033820935856. PubMed ID: 32799782
[TBL] [Abstract][Full Text] [Related]
16. Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Barlogie B; Jagannath S; Desikan KR; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
Blood; 1999 Jan; 93(1):55-65. PubMed ID: 9864146
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
18. Circular RNA_0000190 and its target microRNA-767-5p are dysregulated, and they are related to risk stratification as well as prognosis in multiple myeloma patients.
Xiang Y; Xu X; Yang B; Wu Z; Jiang R; Xie Y
Ir J Med Sci; 2022 Apr; 191(2):671-679. PubMed ID: 33864191
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
20. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
[Next] [New Search]